Keary IP, Ravasio R, Fullarton JR, Manzoni P, et al. A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29-35 weeks' gestational age. PLoS One 2023;18:e0289828.
PMID: 37561741